Technical Analysis for BCRX - BioCryst Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade A 7.1 0.71% 0.05
BCRX closed up 0.71 percent on Friday, August 17, 2018, on 71 percent of normal volume.

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Up
See historical BCRX trend table...

Date Alert Name Type % Chg
Aug 17 Calm After Storm Range Contraction 0.00%
Aug 17 Wide Bands Range Expansion 0.00%
Aug 16 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.71%
Aug 16 Calm After Storm Range Contraction 0.71%
Aug 16 Wide Bands Range Expansion 0.71%
Aug 15 Spinning Top Other 3.20%
Aug 15 Calm After Storm Range Contraction 3.20%
Aug 15 Upper Bollinger Band Walk Strength 3.20%
Aug 15 Wide Bands Range Expansion 3.20%
Aug 15 Overbought Stochastic Strength 3.20%

Older signals for BCRX ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops novel drugs that block key enzymes involved in the pathogenesis of diseases. The company integrates the disciplines of biology, crystallography, medicinal chemistry, and computer modeling to discover and develop small molecule pharmaceuticals through the structure-guided drug design process. Its product candidates include peramivir, an intravenous neuraminidase inhibitor, which is approved for seasonal influenza in Japan and Korea, as well as in Phase III clinical trials for acute influenza; ulodesine, an oral purine nucleoside phosphorylase inhibitor, which has completed Phase II clinical trials for the treatment of gout; and forodesine, an oral purine nucleoside phosphorylase inhibitor that is in Phase II clinical trials for oncology. The company's product candidates also comprise BCX4161, a Phase I oral serine protease inhibitor for kallikrein hereditary angioedema; and BCX4430, a preclinical, RNA dependent-RNA polymerase inhibitor for treating Filoviruses. It has collaborative relationships with Mundipharma International Holdings Limited for the development and commercialization of forodesine; and Shionogi & Co., Ltd. and Green Cross Corporation for the development and commercialization of peramivir. Biocryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Is BCRX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 7.49
52 Week Low 4.12
Average Volume 824,022
200-Day Moving Average 5.3694
50-Day Moving Average 6.0664
20-Day Moving Average 6.3135
10-Day Moving Average 6.801
Average True Range 0.3776
ADX 24.74
+DI 29.2408
-DI 14.3906
Chandelier Exit (Long, 3 ATRs ) 6.3572
Chandelier Exit (Short, 3 ATRs ) 6.5428
Upper Bollinger Band 7.5212
Lower Bollinger Band 5.1058
Percent B (%b) 0.83
BandWidth 38.257702
MACD Line 0.3155
MACD Signal Line 0.2186
MACD Histogram 0.0969
Fundamentals Value
Market Cap 571.04 Million
Num Shares 80.4 Million
EPS -0.62
Price-to-Earnings (P/E) Ratio -11.45
Price-to-Sales 11.43
Price-to-Book 13.91
PEG Ratio -0.28
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 7.56
Resistance 3 (R3) 7.56 7.40 7.48
Resistance 2 (R2) 7.40 7.29 7.40 7.46
Resistance 1 (R1) 7.25 7.21 7.33 7.25 7.43
Pivot Point 7.10 7.10 7.14 7.10 7.10
Support 1 (S1) 6.95 6.98 7.02 6.95 6.77
Support 2 (S2) 6.79 6.91 6.79 6.74
Support 3 (S3) 6.64 6.79 6.72
Support 4 (S4) 6.64